129 related articles for article (PubMed ID: 18193218)
21. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
22. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
23. 17AAG-induced internalisation of HER2-specific Affibody molecules.
Göstring L; Lindegren S; Gedda L
Oncol Lett; 2016 Oct; 12(4):2574-2580. PubMed ID: 27698830
[TBL] [Abstract][Full Text] [Related]
24. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
25. Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway.
Bowers LW; Wiese M; Brenner AJ; Rossi EL; Tekmal RR; Hursting SD; deGraffenried LA
PLoS One; 2015; 10(12):e0145452. PubMed ID: 26709918
[TBL] [Abstract][Full Text] [Related]
26. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
27. Quercetin induces caspase-dependent extrinsic apoptosis through inhibition of signal transducer and activator of transcription 3 signaling in HER2-overexpressing BT-474 breast cancer cells.
Seo HS; Ku JM; Choi HS; Choi YK; Woo JK; Kim M; Kim I; Na CH; Hur H; Jang BH; Shin YC; Ko SG
Oncol Rep; 2016 Jul; 36(1):31-42. PubMed ID: 27175602
[TBL] [Abstract][Full Text] [Related]
28. Targeted Delivery of Deoxycytidine Kinase to Her2-Positive Cells Enhances the Efficacy of the Nucleoside Analog Fludarabine.
Koduvayur SP; Su Y; Kay BK; Lavie A
PLoS One; 2016; 11(6):e0157114. PubMed ID: 27280468
[TBL] [Abstract][Full Text] [Related]
29. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ
Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643
[TBL] [Abstract][Full Text] [Related]
30. Granting specificity for breast cancer cells using a hepatitis B core particle with a HER2-targeted affibody molecule.
Nishimura Y; Mimura W; Mohamed Suffian IF; Amino T; Ishii J; Ogino C; Kondo A
J Biochem; 2013 Mar; 153(3):251-6. PubMed ID: 23235317
[TBL] [Abstract][Full Text] [Related]
31. [The effect of HER2/neu overexpression on p53 gene expression, cell proliferation and sensitivity to gamma-irradiation via the PI3K/Akt pathway in breast cancer cell MCF7].
Zheng L; Ren JQ; Chen Q; Zhang HP; Zhu HG
Zhonghua Zhong Liu Za Zhi; 2004 Oct; 26(10):594-7. PubMed ID: 15634518
[TBL] [Abstract][Full Text] [Related]
32. Treatment of HER2-expressing breast cancer and ovarian cancer cells with alpha particle-emitting 227Th-trastuzumab.
Heyerdahl H; Krogh C; Borrebæk J; Larsen Å; Dahle J
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):563-70. PubMed ID: 21195878
[TBL] [Abstract][Full Text] [Related]
33. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
34. Radiosensitivity patterns of four human ovarian cancer cell lines in vitro.
Petru E; Sevin BU; Gottlieb C
Gynecol Oncol; 1997 Mar; 64(3):490-2. PubMed ID: 9062157
[TBL] [Abstract][Full Text] [Related]
35. DNA-affibody nanoparticles for inhibiting breast cancer cells overexpressing HER2.
Zhang Y; Jiang S; Zhang D; Bai X; Hecht SM; Chen S
Chem Commun (Camb); 2017 Jan; 53(3):573-576. PubMed ID: 27975087
[TBL] [Abstract][Full Text] [Related]
36. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
37. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
[TBL] [Abstract][Full Text] [Related]
38. Genistein sensitizes inhibitory effect of tamoxifen on the growth of estrogen receptor-positive and HER2-overexpressing human breast cancer cells.
Mai Z; Blackburn GL; Zhou JR
Mol Carcinog; 2007 Jul; 46(7):534-42. PubMed ID: 17295235
[TBL] [Abstract][Full Text] [Related]
39. Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation.
Williams JR; Zhang Y; Zhou H; Gridley DS; Koch CJ; Slater JM; Little JB
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):909-17. PubMed ID: 19014780
[TBL] [Abstract][Full Text] [Related]
40. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474).
Mason JK; Fu M; Chen J; Thompson LU
J Nutr Biochem; 2015 Jan; 26(1):16-23. PubMed ID: 25441844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
